been implicated as putative mechanisms for these observations. Most notable among these are the genes that regulate the balance between various members of the matrix metalloproteinase (MMP) family and their tissue inhibitors (TIMPs).
Gene expression studies have documented increased expression of several MMPs, particularly MMP-2 and the ratio of MMP-2 to its tissue inhibitor, TIMP-1, in aortic tissues from BAV patients compared with subjects with a tricuspid aortic valve with or without aortic aneurysms (10 -12) . There is general agreement that this differential pattern of gene expression contributes to the classic pathological finding of aortic medial degeneration (4), characterized by loss of collagen and elastin fragmentation in the aortas of patients with BAV (10, 11) .
Another interesting observation is that deficiency of endothelium-derived nitric oxide, a key regulator of endothelium-dependent flow-mediated vasodilation, also seems to play a role in the defective valvulogenesis of BAV. In an experimental study, Lee et al. (13) showed that endothelium-derived nitric oxide synthase (eNOS) knockout mice had a significantly higher likelihood of developing BAV than control mice. This is corroborated by human studies documenting lower eNOS gene expression in the ascending aortas of BAV patients than in ascending aortas of control subjects with a tricuspid aortic valve (14) .
The study by Tzemos et al. (15) in this issue of the Journal provides an integrating view of the aforementioned pathophysiological factors in BAV patients. In their observational study, Tzemos et al. (15) cross-sectionally evaluated 32 men with BAV, without significant aortic stenosis, who were classified as having nondilated or dilated ascending aortas. Brachial artery flow-mediated vasodilation, carotidfemoral pulse wave velocity (PWV), circulating plasma levels of MMP-2 and -9, as well as their respective tissue inhibitors, TIMP-1 and -2, were measured in the 2 BAV groups and in 16 healthy male control subjects. The investigators found that plasma levels of MMP-2 were higher in men with BAV and dilated aortas compared with both BAV subjects with nondilated aortas and normal control subjects. However, the plasma levels of MMP-9, TIMP-1, and TIMP-2 did not differ among the 3 study groups. Although plasma levels of MMPs do not necessarily mirror their tissue activity (16) , the feasibility and ease of measuring plasma MMPs compared with in vivo determination of their activity in aortic tissue render plasma levels of MMPs an attractive candidate as a prognostic marker for future ascending aortic dilation in BAV patients.
The finding of impaired flow-mediated vasodilation, a hallmark of systemic endothelial dysfunction, in BAV patients with dilated aortas but not in those without dilated aortas suggests that endothelial dysfunction may represent a risk factor for the development of ascending aortic dilation. This finding provides a preliminary rationale for investigating whether statins, which are known to have salutary effects on endothelial function (17) , can ameliorate BAV-related ascending aortic dilation.
Consistent with previous studies (7,18), Tzemos et al. (15) observed a higher PWV in BAV patients with dilated aortas compared with those with nondilated aortas and with normal control subjects. However, the PWV was similar in BAV patients with nondilated aortas and normal control subjects. According to the Moens-Korteweg equation: PWV ϭ ͌Eh/D, where Eh is the aortic elastance-wall thickness product, is the density of blood, and D is the vessel diameter, PWV is inversely related to the square root of the aortic diameter. Thus, for a given Eh, a larger vessel diameter would be expected to result in a lower PWV. However, in the study by Tzemos et al. (15) , subjects with dilated aortas had a higher PWV than the other 2 groups, who had smaller aortic root diameters. This finding indicates that the lowering effect of the larger aortic root diameter on PWV in BAV patients with dilated aortas was counteracted by a more pronounced increase in the aortic elastance-wall thickness product, reflecting the pathological alterations in the aortic wall of BAV patients with dilated aortas.
The cross-sectional design and the exclusion of women from the study sample are the 2 most important limitations of the study by Tzemos et al. (15) . Nonetheless, this study lays the groundwork for the future development of a risk stratification paradigm for predicting the development of ascending aortic dilation in patients with BAV. If the findings reported by Tzemos et al. (15) are corroborated in prospective studies, documenting that they pre-date ascending aortic dilation, they may provide useful tools for risk stratification and thus guide surveillance and clinical management of patients with BAV.
